Novel Therapies Targeting Kidney Disease


Latest Press Releases
Press releases
  • 25 Mar 2025

    Two-thirds of patients enrolled in Guard Therapeutics' Phase 2b POINTER study

    Read more
  • 19 Mar 2025  ·  Regulatory information

    Guard Therapeutics publishes information document regarding rights issue

    Read more
  • 10 Mar 2025  ·  Regulatory information

    The Board of Directors of Guard Therapeutics has resolved on a previously announced rights issue of approximately SEK 150 million

    Read more
  • 27 Feb 2025  ·  Regulatory information

    Guard Therapeutics announces positive outcome from first independent safety data review in Phase 2b POINTER study

    Read more
Show more
In focus
  • 17 Oct 2024 / Presentation

    Guard presents at Redeye Theme "Cardiovascular & Metabolic Diseases Event 2024"

    Read more
  • 23 Sep 2024 / Presentation

    CEO Tobias Agervald appears on BiotechTV

    Read more
  • 19 Sep 2024 / Presentation

    Presentation at Pareto Securities' 15th Annual Healthcare Conference

    Read more
  • 30 Jan 2024 / Presentation

    Guard Therapeutics R&D update January 30, 2024

    Read more
Show more
Upcoming events
  • 04 Apr 2025

    Michael Reusch, faculty member at the Kidney Disease Clinical Trialists Workshop April 4-5

    Read more
  • 14 Apr 2025

    Annual Report 2024 (approximate date)

    Read more
  • 05 May 2025

    Interim report January-March 2025

    Read more
  • 15 May 2025

    Annual General Meeting 2025

    Read more
Event calendar/Financial calendar